SG11202100269VA - Compounds for use in the treatment of fascioliasis - Google Patents
Compounds for use in the treatment of fascioliasisInfo
- Publication number
- SG11202100269VA SG11202100269VA SG11202100269VA SG11202100269VA SG11202100269VA SG 11202100269V A SG11202100269V A SG 11202100269VA SG 11202100269V A SG11202100269V A SG 11202100269VA SG 11202100269V A SG11202100269V A SG 11202100269VA SG 11202100269V A SG11202100269V A SG 11202100269VA
- Authority
- SG
- Singapore
- Prior art keywords
- fascioliasis
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811695.4A GB201811695D0 (en) | 2018-07-17 | 2018-07-17 | Compounds for use in the treatment of fascioliasis |
| PCT/EP2019/069134 WO2020016235A1 (en) | 2018-07-17 | 2019-07-16 | Compounds for use in the treatment of fascioliasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100269VA true SG11202100269VA (en) | 2021-02-25 |
Family
ID=63273364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100269VA SG11202100269VA (en) | 2018-07-17 | 2019-07-16 | Compounds for use in the treatment of fascioliasis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210230169A1 (en) |
| EP (1) | EP3823728A1 (en) |
| JP (1) | JP7449270B2 (en) |
| KR (1) | KR20210032407A (en) |
| CN (1) | CN112512636B (en) |
| AU (1) | AU2019304487B2 (en) |
| BR (1) | BR112021000576A2 (en) |
| GB (1) | GB201811695D0 (en) |
| PH (1) | PH12021550093A1 (en) |
| SG (1) | SG11202100269VA (en) |
| WO (1) | WO2020016235A1 (en) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH590862A5 (en) * | 1974-02-26 | 1977-08-31 | Ciba Geigy Ag | Isothiocyanato-substd. (2)-phenyl-imidazo (1,2-a)-pyridines prodn. - from corresp. amine and thiocarbonic acid derivs., useful as anthelmintics |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| US7875613B2 (en) * | 2006-10-30 | 2011-01-25 | Hybrigenics Sa | Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| US8895745B2 (en) * | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| WO2009133127A1 (en) * | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
| US8975265B2 (en) * | 2010-07-12 | 2015-03-10 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrimidines and —pyridines |
| JP5822944B2 (en) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Disubstituted imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment of hyperproliferative disorders |
| BR112014026184B1 (en) * | 2012-04-20 | 2019-04-24 | Merial, Inc. | PARASITICIDIC COMPOSITIONS UNDERSTANDING BENZIMIDAZOLE DERIVATIVES, METHODS AND THEIR USES |
| JP2016500073A (en) | 2012-11-19 | 2016-01-07 | ノバルティス アーゲー | Compounds and compositions for the treatment of parasitic diseases |
| CN105164124B (en) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | For treating compound and the compositionss of parasitic disease |
| AU2013372386B2 (en) * | 2013-01-10 | 2018-04-19 | Merck Patent Gmbh | Piperidinylcarbazole as antimalarial |
| CA2953843C (en) * | 2014-07-04 | 2023-03-14 | Merck Patent Gmbh | Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity |
| WO2016097759A1 (en) | 2014-12-19 | 2016-06-23 | Aberystwyth University | Anthelmintic compounds |
| EP3270694A4 (en) | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CR20190101A (en) * | 2016-09-02 | 2019-07-04 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| GB201700692D0 (en) | 2017-01-16 | 2017-03-01 | Salvensis | Novel compounds and their use in the treatment of schistosomiasis |
-
2018
- 2018-07-17 GB GBGB1811695.4A patent/GB201811695D0/en not_active Ceased
-
2019
- 2019-07-16 EP EP19742552.3A patent/EP3823728A1/en active Pending
- 2019-07-16 AU AU2019304487A patent/AU2019304487B2/en active Active
- 2019-07-16 KR KR1020217003345A patent/KR20210032407A/en unknown
- 2019-07-16 CN CN201980047163.6A patent/CN112512636B/en active Active
- 2019-07-16 SG SG11202100269VA patent/SG11202100269VA/en unknown
- 2019-07-16 WO PCT/EP2019/069134 patent/WO2020016235A1/en unknown
- 2019-07-16 US US17/259,795 patent/US20210230169A1/en active Pending
- 2019-07-16 JP JP2021501295A patent/JP7449270B2/en active Active
- 2019-07-16 BR BR112021000576-5A patent/BR112021000576A2/en unknown
-
2021
- 2021-01-14 PH PH12021550093A patent/PH12021550093A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201811695D0 (en) | 2018-08-29 |
| US20210230169A1 (en) | 2021-07-29 |
| BR112021000576A2 (en) | 2021-04-06 |
| JP7449270B2 (en) | 2024-03-13 |
| KR20210032407A (en) | 2021-03-24 |
| EP3823728A1 (en) | 2021-05-26 |
| CN112512636A (en) | 2021-03-16 |
| AU2019304487B2 (en) | 2024-05-02 |
| AU2019304487A1 (en) | 2021-03-11 |
| JP2021530509A (en) | 2021-11-11 |
| PH12021550093A1 (en) | 2021-09-27 |
| WO2020016235A1 (en) | 2020-01-23 |
| CN112512636B (en) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Esketamine for the treatment of depression | |
| SI3416957T1 (en) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| EP3826721C0 (en) | Naphthyridine compounds and uses thereof | |
| IL283948A (en) | Methods for the treatment of depression | |
| PT3416945T (en) | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | |
| IL276482A (en) | Compounds for the treatment of pain | |
| IL277502A (en) | Compounds and uses thereof | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| HK1256164A1 (en) | Agents for use in the treatment of glioma | |
| IL277749A (en) | Pladienolide compounds and their use | |
| IL279483A (en) | Cyanotriazole compounds and uses thereof | |
| EP3440052C0 (en) | Compounds for use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| GB2592803B (en) | Compounds for use in preventing or treating athlete overtraining | |
| PT3191112T (en) | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| EP3638219C0 (en) | Composition comprising terpinene-4-ol for the treatment of demodicosis | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency |